ERBB2 and breast carcinoma: In this context, an example of this study is given by the CALGB 40601 clinical trial, a randomized phase III trial evaluating HER2 targeting with paclitaxel plus trastuzumab with or without lapatinib in HER2-positive patients with operable HER2-positive breast cancer [85].